ZNF317 Inhibitors
Chemical inhibitors of ZNF317 can influence the protein's function through various mechanisms of action. Palbociclib, by selectively inhibiting cyclin-dependent kinases CDK4 and CDK6, can disrupt the cell cycle, which is essential for the proper functioning of cell cycle-regulated proteins such as ZNF317. This disruption can lead to altered cell cycle progression, affecting ZNF317's role within this process. MG-132, a potent proteasome inhibitor, can prevent the degradation of proteins that interact with ZNF317, resulting in the accumulation of these regulatory proteins and potentially inhibiting ZNF317's function. Similarly, proteasome inhibition by MG-132 can also lead to increased levels of proteins that control the stability and localization of ZNF317, further influencing its activity.
Additional compounds such as LY294002, a PI3K inhibitor, can reduce phosphorylation of downstream targets that are necessary for ZNF317's activity. Rapamycin's inhibition of mTOR signaling can affect pathways where ZNF317 may play a role, particularly those associated with cellular growth and metabolism. Staurosporine, a broad-spectrum kinase inhibitor, can alter the phosphorylation state of ZNF317, potentially affecting its protein interactions or DNA binding capabilities. Inhibitors like Dasatinib, which targets tyrosine kinases, can disrupt the function of proteins that regulate or interact with ZNF317 by inhibiting phosphorylation-dependent protein interactions. The MEK inhibitors U0126 and PD98059 can reduce the activation of ERK pathway, which may be involved in the regulation of ZNF317. Inhibitors of p38 MAPK (SB203580) and JNK (SP600125) can suppress the activation of proteins involved in the regulation of ZNF317's function in response to stress signals. LFM-A13, an inhibitor of Bruton's tyrosine kinase, and PP2, a selective inhibitor of Src family tyrosine kinases, can disrupt signaling pathways that may regulate ZNF317's activity through phosphorylation cascades.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. ZNF317 is a zinc finger protein that may play a role in cell cycle progression. Inhibition of CDK4/6 by Palbociclib could disrupt the cell cycle, thereby inhibiting the function of cell cycle-regulated proteins like ZNF317. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a potent proteasome inhibitor. By inhibiting the proteasome, MG-132 can prevent the degradation of proteins that regulate the stability and localization of ZNF317, leading to an accumulation of regulatory proteins that could inhibit ZNF317 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in multiple signaling pathways. Inhibition of PI3K can lead to reduced phosphorylation of downstream targets that may be necessary for ZNF317's activity or localization within the cell. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTOR (mechanistic target of rapamycin), which is a crucial regulator of cell growth and metabolism. Inhibition of mTOR can disrupt signaling pathways that ZNF317 may be involved in, particularly those related to growth and proliferation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases. By inhibiting a broad spectrum of kinases, it could affect the phosphorylation state of ZNF317, possibly inhibiting its ability to interact with other proteins or bind DNA. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor, particularly of the Src family kinases. Since tyrosine phosphorylation can regulate protein-protein interactions, Dasatinib can inhibit the function of proteins that interact with or regulate ZNF317. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. As many zinc finger proteins are regulated by ERK signaling, U0126 could inhibit pathways that activate or modulate the function of ZNF317. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, a kinase involved in response to stress signals. Inhibition of p38 MAPK can suppress the activation of proteins that may be involved in the regulation of ZNF317's function in stress response. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is implicated in the control of a number of transcription factors. By inhibiting JNK, SP600125 could prevent the activation of transcriptional regulatory proteins that control ZNF317 activity. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
LFM-A13 is an inhibitor of Bruton's tyrosine kinase (BTK). BTK is part of signal transduction pathways that could regulate the activity of various proteins, potentially including ZNF317, through phosphorylation cascades. | ||||||